Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
CK0804 is an allogeneic, off‑the‑shelf Treg cell therapy.
Cytiva Navigating cell therapy WP 4
Alternative commercialisation models offer lifeline to future of gene therapies
Cell and gene therapy investment strategy pivots as funding dries up
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
Regeneron and Tessera join forces to forge in vivo AATD gene therapy
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
IASO Bio gains Hong Kong approval for Fucaso application
UK-developed leukaemia cell therapy to be offered on NHS
